In the Claims:

Claims 1-26 (Cancelled)

27. (Currently Amended): An isolated, recombinant polypeptide comprising a member selected from the group consisting of

- (a) the amino acid sequence SEQ ID NO:2 and
- (b) an immunogenic fragment of at least 15 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the to a polypeptide having the sequence of SEQ ID NO:2; wherein the immunogenic fragment is selected from one of the following contiguous segments of SEQ ID NO:2:

<u>1-15; 2-16; 3-17; 4-18; 5-19; 6-20; 7-21; 8-22; 9-23; 10-24;</u>

11-25; 12-26; 13-27; 14-28; 15-29; 16-30; 17-31; 18-32; 19-33; 20-34;

21-35; 22-36; 23-37; 24-38; 25-39; 26-40; 27-41; 28-42; 29-43; 30-44;

31-45; 32-46; 33-47; 34-48; 45-49; 46-50; 37-51; 38-52; 39-53; 40-54;

41-55; 42-56; 43-57; 44-58; 45-59; 46-60; 47-61; 48-62; 49-63; 50-64;

<u>51-65</u>; <u>52-66</u>; <u>53-67</u>; <u>54-68</u>; <u>55-69</u>; <u>56-70</u>; <u>57-71</u>; <u>58-72</u>; <u>59-73</u>; <u>60-74</u>;

61-75; 62-76; 63-77; 64-78; 65-79; 66-80; 67-81; 68-82; 69-83; 70-84;

71-85; 72-86; 73-87; 74-88; 75-89; 76-90; 77-91; 78-92; 79-93; 80-94;

81-95; 82-96; 83-97; 84-98; 85-99; 86-100; 87-101; 88-102; 89-103; 90-104;

91-105; 92-106; 93-107; 94-108; 95-109; 96-110; 97-111; 98-112; 99-113; 100-114;

101-115; 102-116; 103-117; 104-118; 105-119; 106-120; 107-121; 108-122; 109-123; 110-124;

111-125; 112-126; 113-127; 114-128; 115-129; 116-130; 117-131; 118-132; 119-133; 120-134;

121-135; 122-136; 123-137; 124-138; 125-139; 126-140; 127-141; 128-142; 129-143; 130-144;

131-145; 132-146; 133-147; 134-148; 135-149; 136-150; 137-151; 138-152; 139-153; 140-154;

141-155; 142-156; 143-157; 144-158; 145-159; 146-160; 147-161; 148-162; 149-163; 150-164;

151-165; 152-166; 153-167; 154-168; 155-169; 156-170; 157-171; 158-172; 159-173; 160-174;

161-175; 162-176; 163-177; 164-178; 165-179; 166-180; 167-181; 168-182; 169-183; 170-184;

171-185; 172-186; 173-187; 174-188; 175-189; 176-190; 177-191;

198-212; 199-213; 200-214;

201-215; 202-216; 203-217; 204-218; 205-219; 206-220; 207-221; 208-222; 209-223; 210-224; 211-225; 212-226; 213-227; 214-228; 215-229; 216-230; 217-231; 218-232; 219-233; 220-234; 221-235; 222-236; 223-237; 224-238; 225-239; 226-240; 227-241; 228-242; 229-243; 230-244; 231-245; 232-246; 233-247; 234-248; 235-249; 236-240; 237-241; 238-252; 239-253; 240-254; 241-255; 242-256; 243-257; 244-258; 245-259; 246-260; 247-261; 248-262; 249-263; 250-264; 251-265; 252-266; 253-267; 254-268; 255-269; 256-270; 257-271; 258-272; 259-273; 260-274; 261-275; 262-276; 263-277; 264-278; 265-279; 266-280; 267-281; 268-282; 269-283; 270-284; 271-285; 272-286; 273-287; 274-288; 275-289; 276-290; 277-291; 278-292; 279-293; 280-294; 281-295; 282-296; 283-297; 284-298; 285-299; 286-300; 287-301; 288-302; 289-303; 290-304; 291-305; 292-306; 293-307; 294-308; 295-309; 296-310; 297-311; 298-312; 299-313; 300-314; 301-315; 302-316; 303-317; 304-318; 305-319; 306-320; 307-321; 308-322; 309-323; 310-324; 311-325; 312-326; 313-327; 314-328; 315-329; 316-330; 317-331; 318-332; 319-333; 320-334; 321-335; 322-336; 323-337; 324-338; 325-339; 326-340; 327-341; 328-342; 329-343; 330-344; 331-345; 332-346; 333-347; 334-348; 335-349; 336-350; 337-351; 338-352; 339-353; 340-354; 341-355; 342-356; 343-357; 344-358; 345-359; 346-360; 347-361; 348-362; 349-363; 350-364; 351-365; 352-366; 353-367; 354-368; 355-369; 356-370; 357-371; 358-372; 359-373; 360-374; 361-375; 362-376; 363-377; 364-378; 365-379; 366-380; 367-381; 368-382; 369-383; 370-384; 371-385; 372-386; 373-387; 374-388; 375-389; <u>376-390</u>; <u>377-391</u>; <u>378-392; <u>379-393</u>; <u>380-394</u>;</u> 381-395; 382-396; 383-397; 384-398; 385-399; 386-400; 387-401; 388-402; 389-403; 390-404; 391-405; 392-406; 393-407; 394-408; 395-409; 396-410; 397-411; 398-412; 399-413; 400-414; 401-415; 402-416; 403-417; 404-418; 405-419; 406-420; 407-421; 408-422; 409-423; 410-424; 411-425; 412-426; 413-427; 414-428; 415-429; 416-430; 417-431; 418-432; 419-433; 420-434; 421-435; 422-436; 423-437; 424-438; 425-439; 426-440; 427-441; 428-442; 429-443; 430-444; 431-445; 432-446; 433-447; 434-448; 435-449; 436-450; 437-451; 438-452; 439-453; 440-454; 441-455; 442-456; 443-457; 444-458; 445-459; 446-460; 447-461; 448-462; 449-463; 450-464; 451-465; 452-466; 453-467; 454-468; 455-469; 456-470; 457-471; 458-472; 459-473; 460-474; 461-475; 462-476; 463-477; 464-478; 465-479; 466-480; 467-481; 468-482; 469-483; 470-484; <u>471-485; 472-486; 473-487; 474-488; 475-489; 476-490; 477-491; 478-</u>492; 479-493; <u>4</u>80-494; 481-495; 482-496; 483-497; 484-498; 485-499; 486-500; 487-501; and 488-502.

28. (Cancelled)

29. (Currently Amended): The isolated, recombinant polypeptide of claim 27, wherein the polypeptide is according to (a).

Claims 30-31 (Cancelled)

32. (Currently Amended): The isolated, recombinant polypeptide of claim 27, wherein the polypeptide is according to (b).

33. (Cancelled)

34. (Currently Amended): The isolated, recombinant polypeptide of claim 27, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2; wherein the immunogenic fragment is selected from one of the following contiguous segments of SEQ ID NO:2:

1-20; 2-21; 3-22; 4-23; 5-24; 6-25; 7-26; 8-27; 9-28; 10-29;

11-30; 12-31; 13-32; 14-33; 15-34; 16-35; 17-36; 18-37; 19-38; 20-39;

21-40; 22-41; 23-42; 24-43; 25-44; 26-45; 27-46; 28-47; 29-48; 30-49;

31-50; 32-51; 33-52; 34-53; 35-54; 36-55; 37-56; 38-57; 39-58; 40-59;

41-60; 42-61; 43-62; 44-63; 45-64; 46-65; 47-66; 48-67; 49-68; 50-69;

51-70; 52-71; 53-72; <u>54-73</u>; <u>55-74</u>; <u>56-75</u>; <u>57-76</u>; <u>58-77</u>; <u>59-78</u>; <u>60-79</u>;

61-80; 62-81; 63-82; 64-83; 65-84; 66-85; 67-86; 68-87; 69-88; 70-89;

71-90; 72-91; 73-92; 74-93; 75-94; 76-95; 77-96; 78-97; 79-98; 80-99;

81-100; 82-101; 83-102; 84-103; 85-104; 86-105; 87-106; 88-107; 89-108; 90-109;

91-110: 92-111: 93-112: 94-113: 95-114: 96-115: 97-116: 98-117: 99-118: 100-119:

101-120; 102-121; 103-122; 104-123; 105-124; 106-125; 107-126; 108-127; 109-128; 110-129; 111-130; 112-131; 113-132; 114-133; 115-134; 116-135; 117-136; 118-137; 119-138; 120-139; 121-140; 122-141; 123-142; 124-143; 125-144; 126-145; 127-146; 128-147; 129-148; 130-149; 131-150; 132-151; 133-152; 134-153; 135-154; 136-155; 137-156; 138-157; 139-158; 140-159; 141-160; 142-161; 143-162; 144-163; 145-164; 146-165; 147-166; 148-167; 149-168; 150-169; 151-170; 152-171; 153-172; 154-173; 155-174; 156-175; 157-176; 158-177; 159-178; 160-179; 161-180; 162-181; 163-182; 164-183; 165-184; 166-185; 167-186; 168-187; 169-188; 170-189; 171-190; 172-191; 198-217; 199-218; 200-219; 201-220; 202-221; 203-222; 204-223; 205-224; 206-225; 207-226; 208-227; 209-228; 210-229; 211-230; 212-231; 213-232; 214-233; 215-234; 216-235; 217-236; 218-237; 219-238; 220-239; 221-240; 222-241; 223-242; 224-243; 225-244; 226-245; 227-246; 228-247; 229-248; 230-249; 231-250; 232-251; 233-252; 234-253; 235-254; 236-255; 237-256; 238-257; 239-258; 240-259; 241-260; 242-261; 243-262; 244-263; 245-264; 246-265; 247-266; 248-267; 249-268; 250-269; 251-270; 252-271; 253-272; 254-273; 255-274; 256-275; 257-276; 258-277; 259-278; 260-279; 261-280; 262-281; 263-282; 264-283; 265-284; 266-285; 267-286; 268-287; 269-288; 270-289; 271-290; 272-291; 273-292; 274-293; 275-294; 276-295; 277-296; 278-297; 279-298; 280-299; 281-300; 282-301; 283-302; 284-303; 285-304; 286-305; 287-306; 288-307; 289-308; 290-309; 291-310; 292-311; 293-312; 294-313; 295-314; 296-315; 297-316; 298-317; 299-318; 300-319; 301-320; 302-321; 303-322; 304-323; 305-324; 306-325; 307-326; 308-327; 309-328; 310-329; 311-330; 312-331; 313-332; 314-333; 315-334; 316-335; 317-336; 318-337; 319-338; 320-339; 321-340; 322-341; 323-342; 324-343; 325-344; 326-345; 327-346; 328-347; 329-348; 330-349; 331-350; 332-351; 333-352; 334-353; 335-354; 336-355; 337-356; 338-357; 339-358; 340-359; 341-360; 342-361; 343-362; 344-363; 345-364; 346-365; 347-366; 348-367; 349-368; 350-369; 351-370; 352-371; 353-372; 354-373; 355-374; 356-375; 357-376; 358-377; 359-378; 360-379; 361-380; 362-381; 363-382; 364-383; 365-384; 366-385; 367-386; 368-387; 369-388; 370-389; 371-390; 372-391; 373-392; 374-393; 375-394; 376-395; 377-396; 378-397; 379-398; 380-399; 381-400; 382-401; 383-402; 384-403; 385-404; 386-405; 387-406; 388-407; 389-408; 390-409; 391-410; 392-411; 393-412; 394-413; 395-414; 396-415; 397-416; 398-417; 399-418; 400-419; 401-420; 402-421; 403-422; 404-423; 405-424; 406-425; 407-426; 408-427; 409-428; 410-429; 411-430; 412-431; 413-432; 414-433; 415-434; 416-435; 417-436; 418-437; 419-438; 420-439; 421-440; 422-441; 423-442; 424-443; 425-444; 426-445; 427-446; 428-447; 429-448; 430-449;

431-450; 432-451; 433-452; 434-453; 435-454; 436-455; 437-456; 438-457; 439-458; 440-459; 441-460; 442-461; 443-462; 444-463; 445-464; 446-465; 447-466; 448-467; 449-468; 450-469; 451-470; 452-471; 453-472; 454-473; 455-474; 456-475; 457-476; 458-477; 459-478; 460-479; 461-480; 462-481; 463-482; 464-483; 465-484; 466-485; 467-486; 468-487; 469-488; 470-489; 471-490; 472-491; 473-492; 474-493; 475-494; 476-495; 477-496; 478-497; 479-498; 480-499; 481-500; 482-501; and 483-502.

35. (Currently Amended): The isolated, recombinant polypeptide of claim 27, wherein the isolated, recombinant polypeptide consists of SEQ ID NO:2.

Claims 36-37 (Cancelled)

38. (Currently Amended): A fusion protein comprising the isolated, recombinant polypeptide of Claim 27.

Claims 39-42 (Cancelled)

- 43. (Currently Amended): An immunogenic composition comprising the <u>isolated</u>, <u>recombinant</u> polypeptide of Claim 27 and a pharmaceutically acceptable carrier.
- 44. (Previously Presented): The immunogenic composition of Claim 43, wherein the immunogenic composition comprises at least one other *Moraxella catarrhalis* antigen.
- 45. (Cancelled)
- 46. (Previously Presented): A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 27.

Claims 47-55 (Cancelled)

56. (New): A fusion protein comprising the isolated, recombinant polypeptide of claim 29.

- 57. (New): An immunogenic composition comprising the isolated, recombinant polypeptide of claim 29.
- 58. (New): A fusion protein comprising the isolated, recombinant polypeptide of claim 32.
- 59. (New): An immunogenic composition comprising the isolated, recombinant polypeptide of claim 32.